Roche says its arthritis drug more effective
ZURICH (Reuters) - Roche Holding AG's MabThera was more effective in treating rheumatoid arthritis (RA) patients than other drugs with a more traditional mode of action, the Swiss drugmaker said on Wednesday.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=whvXnD" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=whvXnD)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=iAzVoI" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=iAzVoI) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=uWacXi" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=uWacXi) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=eHLcWi" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=eHLcWi)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/309425434" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/309425434/idUSL1137297520080611